Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
Status and phase
Completed
Phase 1
Conditions
Healthy
Diabetes
Treatments
Drug: semaglutide
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.
Enrollment
27 patients
Sex
Male
Ages
18 to 64 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Good general health
- Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)
Exclusion criteria
- Males who are not willing to use two acceptable forms of highly effective contraception
- Participation in another clinical trial within 90 days
- Any chronic disorder or severe disease
- Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing
- Subjects who are smokers
- Subjects who have donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Crossover Assignment
Masking
None (Open label)
27 participants in 2 patient groups
Period 1: NN9924 with 50 mL water
Experimental group
Treatment:
Drug: semaglutide
Period 2: NN9924 with 240 mL water
Experimental group
Treatment:
Drug: semaglutide
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems